[Paper-level Aggregated] PMCID: PMC4999563

Evidence Type(s): Oncogenic

Summary: Mutation: V600E | Summary: The BRAF V600E mutation is known to contribute to tumor development and progression, supporting its classification as an oncogenic variant.

Gene→Variant (gene-first): BRAF(673):V600E

Genes: BRAF(673)

Variants: V600E

[Paper-level Aggregated] PMCID: PMC4999563

Evidence Type(s): Prognostic

Summary: Mutation: G12C | Summary: The KRAS G12C mutation is associated with inferior progression-free and overall survival in metastatic colorectal cancer (mCRC) patients compared to those with non-mutated tumors. It correlates with a median overall survival (OS) of 16.8 months, indicating a negative prognostic effect.

Evidence Type: Prognostic Mutation: G13D | Summary: The KRAS G13D mutation is associated with inferior progression-free and overall survival in mCRC patients compared to those with non-mutated tumors. It shows a median progression-free survival (PFS) of 8.8 months and a trend towards inferior overall survival (OS), suggesting potential negative prognostic implications.

Evidence Type: Prognostic Mutation: G12D | Summary: The KRAS G12D variant shows a median PFS of 10.5 months and a median overall survival (OS) of 25.2 months, suggesting its impact on disease outcome, but did not show a significant impact on overall survival, indicating it may not have a strong prognostic role.

Evidence Type: Prognostic Mutation: G12V | Summary: The KRAS G12V variant did not demonstrate a significant impact on overall survival (OS) and had a negative prognostic effect on progression-free survival (PFS) in the multivariate analysis, suggesting limited prognostic value.

Gene→Variant (gene-first): KRAS(3845):G12C KRAS(3845):G13D KRAS(3845):G12D KRAS(3845):G12V

Genes: KRAS(3845)

Variants: G12C G13D G12D G12V

[Paper-level Aggregated] PMCID: PMC4999563

Evidence Type(s): Diagnostic

Summary: Mutation: V600E | Summary: The presence of the BRAF V600E mutation is used to classify and confirm the subtype of tumors in which it is found, indicating its diagnostic relevance.

Gene→Variant (gene-first): BRAF(673):V600E

Genes: BRAF(673)

Variants: V600E

[Paragraph-level] PMCID: PMC4999563 Section: RESULTS PassageIndex: 11

Evidence Type(s): Prognostic

Summary: Evidence Type: Prognostic | Mutation: G12C | Summary: The KRAS exon 2 G12C variant correlates with inferior overall survival (OS) compared to non-mutated tumors, indicating a negative prognostic effect. Evidence Type: Prognostic | Mutation: G13D | Summary: The KRAS exon 2 G13D variant shows a trend towards inferior overall survival (OS) compared to non-mutated tumors, suggesting a potential negative prognostic effect. Evidence Type: Prognostic | Mutation: G12V | Summary: The KRAS exon 2 G12V mutation variant had a negative prognostic effect on progression-free survival (PFS) in the multivariate analysis.

Gene→Variant (gene-first): 3845:G12C 3845:G12D 3845:G12V 3845:G13D

Genes: 3845

Variants: G12C G12D G12V G13D

[Paragraph-level] PMCID: PMC4999563 Section: RESULTS PassageIndex: 10

Evidence Type(s): Prognostic

Summary: Evidence Type: Prognostic | Mutation: G13D | Summary: The G13D mutation is associated with a median progression-free survival (PFS) of 8.8 months, indicating its correlation with disease outcome. Evidence Type: Prognostic | Mutation: G12D | Summary: The G12D variant shows a median PFS of 10.5 months and a median overall survival (OS) of 25.2 months, suggesting its impact on disease outcome. Evidence Type: Prognostic | Mutation: G12C | Summary: The G12C mutation is linked to a median overall survival (OS) of 16.8 months, indicating its association with disease outcome.

Gene→Variant (gene-first): 3845:A146T 3845:G12C 3845:G12D 3845:G13D 3845:Q61H

Genes: 3845

Variants: A146T G12C G12D G13D Q61H

[Paragraph-level] PMCID: PMC4999563 Section: RESULTS PassageIndex: 4

Evidence Type(s): Diagnostic, Oncogenic

Summary: Evidence Type: Diagnostic | Mutation: V600E | Summary: The presence of the BRAF V600E mutation is used to classify and confirm the subtype of tumors in which it is found, indicating its diagnostic relevance. Evidence Type: Oncogenic | Mutation: V600E | Summary: The BRAF V600E mutation is known to contribute to tumor development and progression, supporting its classification as an oncogenic variant.

Gene→Variant (gene-first): 673:V600E

Genes: 673

Variants: V600E

[Paragraph-level] PMCID: PMC4999563 Section: ABSTRACT PassageIndex: 9

Evidence Type(s): Prognostic

Summary: Evidence Type: Prognostic | Mutation: G12C | Summary: The KRAS G12C mutation is associated with poor survival outcomes in mCRC patients compared to those with non-mutated tumors. Evidence Type: Prognostic | Mutation: G13D | Summary: The KRAS G13D mutation is associated with poor survival outcomes in mCRC patients compared to those with non-mutated tumors.

Gene→Variant (gene-first): 3845:G12C 3845:G13D

Genes: 3845

Variants: G12C G13D

[Paragraph-level] PMCID: PMC4999563 Section: ABSTRACT PassageIndex: 7

Evidence Type(s): Prognostic

Summary: Evidence Type: Prognostic | Mutation: G12C | Summary: The KRAS G12C variant is associated with inferior overall survival (OS) compared to unmutated tumors, indicating a prognostic role. Evidence Type: Prognostic | Mutation: G13D | Summary: The KRAS G13D variant shows a similar trend for inferior overall survival (OS), suggesting it may also have prognostic implications. Evidence Type: Prognostic | Mutation: G12D | Summary: The KRAS G12D variant did not show a significant impact on overall survival (OS), indicating it may not have a strong prognostic role. Evidence Type: Prognostic | Mutation: G12V | Summary: The KRAS G12V variant also did not demonstrate a significant impact on overall survival (OS), suggesting limited prognostic value.

Gene→Variant (gene-first): 3845:G12C 3845:G12D 3845:G12V 3845:G13D

Genes: 3845

Variants: G12C G12D G12V G13D

[Paragraph-level] PMCID: PMC4999563 Section: ABSTRACT PassageIndex: 1

Evidence Type(s): Prognostic

Summary: Evidence Type: Prognostic | Mutation: G12C | Summary: The KRAS G12C mutation is associated with inferior progression-free and overall survival in metastatic colorectal cancer patients compared to those with non-mutated tumors. Evidence Type: Prognostic | Mutation: G13D | Summary: The KRAS G13D mutation is associated with inferior progression-free and overall survival in metastatic colorectal cancer patients compared to those with non-mutated tumors.

Gene→Variant (gene-first): 3845:G12C 3845:G13D

Genes: 3845

Variants: G12C G13D

[Paper-level Aggregated] PMCID: PMC4999563

Evidence Type(s): Prognostic, Oncogenic, Functional

Justification: Prognostic: The text indicates that mutations in KRAS, particularly the G12C and G13D variants, are associated with inferior overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer patients compared to non-mutated tumors. Oncogenic: The presence of KRAS mutations, including G12C and G13D, is linked to poor survival outcomes, suggesting that these mutations contribute to the oncogenic process in colorectal cancer. Functional: The analysis of various KRAS mutations, including A146T, Q61H, and others, indicates that these variants were evaluated for their impact on efficacy endpoints, suggesting a functional role in tumor behavior and treatment response.

Gene→Variant (gene-first): KRAS(3845):A146T KRAS(3845):G12C KRAS(3845):G12D KRAS(3845):G13D KRAS(3845):Q61H KRAS(3845):G12V BRAF(673):V600E

Genes: KRAS(3845) BRAF(673)

Variants: A146T G12C G12D G13D Q61H G12V V600E

[Paragraph-level] PMCID: PMC4999563 Section: RESULTS PassageIndex: 11

Evidence Type(s): Prognostic, Oncogenic

Justification: Prognostic: The passage discusses the correlation of KRAS exon 2 variants, specifically G12C and G13D, with overall survival (OS) and progression-free survival (PFS), indicating their impact on disease outcome independent of therapy. Oncogenic: The mention of KRAS exon 2 variants suggests their role in tumor development or progression, as they are associated with inferior survival outcomes in patients with mutated tumors compared to non-mutated tumors.

Gene→Variant (gene-first): 3845:G12C 3845:G12D 3845:G12V 3845:G13D

Genes: 3845

Variants: G12C G12D G12V G13D

[Paragraph-level] PMCID: PMC4999563 Section: RESULTS PassageIndex: 10

Evidence Type(s): Prognostic, Diagnostic

Justification: Prognostic: The passage discusses the median progression-free survival (PFS) and overall survival (OS) associated with specific KRAS mutations, indicating a correlation with disease outcomes independent of therapy. Diagnostic: The mention of KRAS exon 2 mutant tumor subtypes suggests that these variants are used to classify or define a specific disease subtype.

Gene→Variant (gene-first): 3845:A146T 3845:G12C 3845:G12D 3845:G13D 3845:Q61H

Genes: 3845

Variants: A146T G12C G12D G13D Q61H

[Paragraph-level] PMCID: PMC4999563 Section: RESULTS PassageIndex: 4

Evidence Type(s): Diagnostic, Oncogenic

Justification: Diagnostic: The passage indicates that tumors carrying BRAF V600E mutations were identified, suggesting an association with the classification of the tumors. Oncogenic: The mention of BRAF V600E mutations in tumors implies a role in tumor development or progression, characteristic of oncogenic variants.

Gene→Variant (gene-first): 673:V600E

Genes: 673

Variants: V600E

[Paragraph-level] PMCID: PMC4999563 Section: ABSTRACT PassageIndex: 9

Evidence Type(s): Prognostic, Diagnostic

Justification: Prognostic: The passage indicates that KRAS G12C and G13D mutations are associated with inferior progression-free survival (PFS) and overall survival (OS) in mCRC patients, suggesting a correlation with disease outcome independent of therapy. Diagnostic: The mention of KRAS mutations being associated with heterogeneous outcomes compared to unmutated tumors implies that these variants can be used to classify or define a disease subtype in mCRC.

Gene→Variant (gene-first): 3845:G12C 3845:G13D

Genes: 3845

Variants: G12C G13D

[Paragraph-level] PMCID: PMC4999563 Section: ABSTRACT PassageIndex: 7

Evidence Type(s): Prognostic, Diagnostic

Justification: Prognostic: The passage discusses the correlation of KRAS mutations, including specific variants like G12C and G13D, with inferior overall survival (OS) and progression-free survival (PFS), indicating their impact on disease outcome independent of therapy. Diagnostic: The passage mentions that mutations in KRAS were diagnosed in tumors, indicating that these mutations are used to classify or define the disease.

Gene→Variant (gene-first): 3845:G12C 3845:G12D 3845:G12V 3845:G13D

Genes: 3845

Variants: G12C G12D G12V G13D

[Paragraph-level] PMCID: PMC4999563 Section: ABSTRACT PassageIndex: 1

Evidence Type(s): Prognostic, Diagnostic

Justification: Prognostic: The passage discusses how KRAS G12C and G13D mutations correlate with inferior progression-free and overall survival in metastatic colorectal cancer patients, indicating their prognostic significance. Diagnostic: The mention of KRAS mutations being associated with tumor characteristics suggests their role in classifying or defining the disease subtype in colorectal cancer.

Gene→Variant (gene-first): 3845:G12C 3845:G13D

Genes: 3845

Variants: G12C G13D

[Paragraph-level] PMCID: PMC4999563 Section: RESULTS PassageIndex: 11

Evidence Type(s): Prognostic, Oncogenic

Justification: Prognostic: The passage discusses the correlation of KRAS exon 2 variants, specifically G12C and G13D, with overall survival (OS) and progression-free survival (PFS), indicating their impact on disease outcome independent of therapy. Oncogenic: The mention of KRAS exon 2 variants suggests their role in tumor development or progression, as they are associated with inferior survival outcomes in patients with mutated tumors compared to non-mutated tumors.

Gene→Variant (gene-first): 3845:G12C 3845:G12D 3845:G12V 3845:G13D

Genes: 3845

Variants: G12C G12D G12V G13D

[Paragraph-level] PMCID: PMC4999563 Section: RESULTS PassageIndex: 10

Evidence Type(s): Prognostic, Diagnostic

Justification: Prognostic: The passage discusses the median progression-free survival (PFS) and overall survival (OS) associated with specific KRAS mutations, indicating a correlation with disease outcomes independent of therapy. Diagnostic: The mention of KRAS exon 2 mutant tumor subtypes suggests that these variants are used to classify or define a specific disease subtype.

Gene→Variant (gene-first): 3845:A146T 3845:G12C 3845:G12D 3845:G13D 3845:Q61H

Genes: 3845

Variants: A146T G12C G12D G13D Q61H

[Paragraph-level] PMCID: PMC4999563 Section: RESULTS PassageIndex: 4

Evidence Type(s): Diagnostic, Oncogenic

Justification: Diagnostic: The passage indicates that tumors carrying BRAF V600E mutations were identified, suggesting an association with the classification of the tumors. Oncogenic: The mention of BRAF V600E mutations in tumors implies a role in tumor development or progression, characteristic of oncogenic variants.

Gene→Variant (gene-first): 673:V600E

Genes: 673

Variants: V600E

[Paragraph-level] PMCID: PMC4999563 Section: ABSTRACT PassageIndex: 9

Evidence Type(s): Prognostic, Diagnostic

Justification: Prognostic: The passage indicates that KRAS G12C and G13D mutations are associated with inferior progression-free survival (PFS) and overall survival (OS) in mCRC patients, suggesting a correlation with disease outcome independent of therapy. Diagnostic: The mention of KRAS mutations being associated with heterogeneous outcomes compared to unmutated tumors implies that these variants can be used to classify or define a disease subtype in mCRC.

Gene→Variant (gene-first): 3845:G12C 3845:G13D

Genes: 3845

Variants: G12C G13D

[Paragraph-level] PMCID: PMC4999563 Section: ABSTRACT PassageIndex: 7

Evidence Type(s): Prognostic, Diagnostic

Justification: Prognostic: The passage discusses the correlation of KRAS mutations, including specific variants like G12C and G13D, with inferior overall survival (OS) and progression-free survival (PFS), indicating their impact on disease outcome independent of therapy. Diagnostic: The passage mentions that mutations in KRAS were diagnosed in tumors, indicating that these mutations are used to classify or define the disease.

Gene→Variant (gene-first): 3845:G12C 3845:G12D 3845:G12V 3845:G13D

Genes: 3845

Variants: G12C G12D G12V G13D

[Paragraph-level] PMCID: PMC4999563 Section: ABSTRACT PassageIndex: 1

Evidence Type(s): Prognostic, Diagnostic

Justification: Prognostic: The passage discusses how KRAS G12C and G13D mutations correlate with inferior progression-free and overall survival in metastatic colorectal cancer patients, indicating their prognostic significance. Diagnostic: The mention of KRAS mutations being associated with tumor characteristics suggests their role in classifying or defining the disease subtype in colorectal cancer.

Gene→Variant (gene-first): 3845:G12C 3845:G13D

Genes: 3845

Variants: G12C G13D